Prostate cancer's silent threat: Early detection is key for South African men

Prostate cancer has earned a reputation as a stealthy adversary for men, often going undetected until it reaches an advanced stage. Lacking obvious early symptoms, this formidable disease can progress unnoticed, striking when least expected. Current statistics reveal a worrying truth: prostate cancer is now the leading cancer affecting South African men and the second deadliest, with a particularly alarming rise in cases among younger demographics.

“Prostate, colorectal, and lung cancer rank the highest amongst the male population in South Africa,” said Vanessa Snow, Head of Medical Affairs at Johnson & Johnson. She highlighted the stark reality that while prostate cancer is manageable if caught early, the threat looms particularly large for men of African heritage, who face an increased risk of developing the disease at a younger age and often in more aggressive forms. Research indicates that one in six black men will be diagnosed with prostate cancer, in contrast to one in eight white men. Furthermore, men of African descent are significantly more likely to be diagnosed at later stages of the disease, impacting their treatment options and long-term outcomes.

Access to healthcare remains a critical factor in the early detection and management of prostate cancer, especially in developing countries. Despite advancements in diagnostics, a lack of awareness and access to screening persists across demographic lines. Snow urges men to take proactive steps, advocating for routine screenings via a Prostate Specific Antigen (PSA) blood test. “The earlier the disease is diagnosed, the greater the chance anyone has of successfully entering a treatment path,” she said.

Emerging scientific advancements also offer hope in combatting this pervasive disease. Genetic testing, which was once inaccessible for the general public, is now showing promise in assessing an individual’s risk of developing prostate cancer and the potential aggressiveness of the disease. According to Andrew Oberholzer, CEO of the Prostate Cancer Foundation of South Africa, certain inherited mutations, particularly the BRCA2 gene, significantly heighten a man’s chances of developing prostate cancer early in life.

Oberholzer explains that there are two types of genetic mutations to consider: germline mutations, which are inherited, and somatic mutations, which occur during a person’s lifetime. Testing for specific somatic genetic mutations can help identify men at high risk who could benefit from new targeted therapies, such as Poly (ADP-ribose) polymerase (PARP) inhibitors. These inhibitors provide a unique approach, repairing damaged DNA and offering new avenues of treatment for certain forms of prostate cancer.

Highlighting the importance of family health, Oberholzer noted that genetic testing not only benefits individuals but can also have wider implications for families. “If a man carries one of these inherited changes or mutations, his children or siblings may also carry the same mutation,” he stated. “By identifying risks early, relatives can opt for proactive screening, improving their chances of avoiding late-stage disease as well.”

In a battle against a disease that often lurks in the shadows, the message is clear: awareness, early detection, and taking proactive measures are vital for South African men, especially as prostate cancer continues to claim lives disproportionately in specific communities. Regular check-ups and embracing the advancements of genetic testing could transform the prognosis for many, turning this silent threat into a conquerable foe.

IOS